Could cause temporary or reversible harm; serious harm is unlikely.
Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity
| Brand name | ENTECAVIR |
| Generic name | ENTECAVIR |
| Active ingredient(s) | ENTECAVIR |
| Distributed by / for | Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534 |
| NDC | 68382-921-06 |
| Full product label | Entecavir Tablets, USP, 1 mg, 30-count bottle, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-921-06. |
| Recalling firm | Zydus Pharmaceuticals (USA) Inc |
| Distribution | Distributed Nationwide in the USA |
| Quantity | 600 30-count bottles |
| Recall initiated | 2025-09-24 |
| Report date | 2025-10-08 |
| Recall completed | — |
| Recall number | D-0002-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Pennington NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗